Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis-Reference-Cited by-同舟云学术

Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis

Published:2011-03-17 Issue:3 Volume:13 Page:244-249
ISSN:1398-2273
Container-title:Transplant Infectious Disease
language:en
Short-container-title:

Author:

Boudreault A.A.,Xie H.,Rakita R.M.,Scott J.D.,Davis C.L.,Boeckh M.,Limaye A.P.

Publisher

Wiley

Subject

Infectious Diseases,Transplantation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1399-3062.2011.00624.x/fullpdf

Reference14 articles.

1. Cytomegalovirus in solid organ transplant recipients;Humar;Am J Transplant,2009

2. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis;Limaye;Transplantation,2006

3. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis;Akalin;Am J Transplant,2003

4. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation;Arthurs;Clin Infect Dis,2008

5. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course;Doyle;Transplantation,2006

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review and Meta-analysis of Optimized CMV Preemptive Therapy and Antiviral Prophylaxis for CMV Disease Prevention in CMV High-Risk (D+R-) Kidney Transplant Recipients;Transplantation Direct;2023-07-12

2. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients;JAMA Internal Medicine;2022-02-01

3. Cytomegalovirus infection in kidney transplant patients: Prevalence, risk factors, and impact on outcome – A local multicentre experience;Transplant Immunology;2021-12

4. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab;International Journal of Infectious Diseases;2021-06

5. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors;JAMA;2020-04-14